Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The company will donate 5000 nebulizers to primary health care centres in rural India
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Philips Patient Monitors IntelliVue MX750 and IntelliVue MX850 pair with advanced software and services to offer clinical decision support, continuous, scalable patient management and enhanced infection control
Approximately five kg tumor was removed in the eight-hour long complicated surgery
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
Subscribe To Our Newsletter & Stay Updated
